Table 1.

Patient characteristics at treatment initiation. In the MSKCC cohort, 346 patients with stage II-IV disease treated with R-Chemo were evaluable for PFS24 status after first line treatment. In the validation FOLL05 Cohort, 484 patients with stage II-IV disease treated with R-Chemo were evaluable for PFS24 status after first line treatment.

	MSKCC (N=346)					FOLL05 (N=484)
	CT staged (N=118)		PET staged (n=228)			CT staged (N=345)		PET staged (n=139)
Characteristic	No.	%	No.	%	P	No.	%	No.	%	P
Age: median (Range)	56 (24–80)		55 (23–85)		0·95	55 (29–75)		56 (32–74)		0·24
Gender
Female	54	46%	99	43%	0·73	164	48%	72	52%	0·42
Male	64	54%	129	57%		181	52%	67	48%
Stage
II	6	5%	13	6%	1·00	33	10%	9	6%	0·37
III/IV	112	95%	215	94%		312	90%	130	94%
FLPI
Low	15	16%	24	12%	0.69	74	21%	31	22%	0.98
Intermediate	30	32%	66	34%		144	42%	57	41%
High	49	52%	105	54%		127	37%	51	37%
Unknown	24		33
LDH
Elevated	31	35%	68	37%		67	19%	28	20%	0.90
Normal	57	65%	117	63%	0·89	278	81%	111	80%
Unknown	30		43
Treatment
R-CHOP	84	71%	154	68%		114	33%	47	34%	0.85
R-CVP	21	18%	41	18%		116	34%	43	31%
R-FM	1	1%	4	2%	0.93	115	33%	49	35%
R-Bendamustine	6	5%	14	6%
Other	6	5%	15	7%
Rituximab maintenance
Yes	27	23%	74	32%		0	0%	0	0%	1·00
No	91	77%	154	68%		345	100%	139	100%
Subsequent HDT/SCT
Autologous	7	6%	20	9%		–		–
Allogeneic	6	5%	12	5%	0.84
Both	3	3%	7	3%
No	102	86%	189	83%		–		–
PFS24 status
PFS24 achievers	83	70%	165	72%	0.71	235	68%	104	75%	0.16
PFS24 failures	35	30%	63	28%		110	32%	35	25%

Abbreviations: FLIPI, Follicular Lymphoma International Prognostic Index; HDT/SCT, high-dose therapy and stem cell transplant; LDH, lactate dehydrogenase; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab plus cyclophosphamide, vincristine, and prednisone; R-FM, rituximab plus fludarabine and mitoxantrone